Taken together, these data indicate that constitutive nuclear YAP localization confers resistance to vemurafenib in BRAFV600E mutant thyroid cancer cell lines by augmenting the relief of feedback activation of the NRG1-HER2/HER3 pathway. Here, YAP1 is linked to thyroid gland carcinoma.